➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Merck
McKinsey
AstraZeneca
Moodys
Mallinckrodt
McKesson

Last Updated: September 26, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR DELSTRIGO

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

All Clinical Trials for Delstrigo

Trial ID Title Status Sponsor Phase Start Date Summary
NCT04233372 ↗ Evaluation of (Doravirine / Lamivudine / Tenofovir Disoproxil Fumarate) (Delstrigo┬«) as a New Strategy for Non-occupational Post Exposure Prophylaxis, a Prospective Open Label Study Not yet recruiting Dr. Josep Mallolas Phase 4 2020-02-15 Subjects who go to emergency room for possible contact to HIV transmission receive Delstrigo as post exposition prophylaxis.
NCT04233372 ↗ Evaluation of (Doravirine / Lamivudine / Tenofovir Disoproxil Fumarate) (Delstrigo┬«) as a New Strategy for Non-occupational Post Exposure Prophylaxis, a Prospective Open Label Study Not yet recruiting David Garcia Cinca Phase 4 2020-02-15 Subjects who go to emergency room for possible contact to HIV transmission receive Delstrigo as post exposition prophylaxis.
NCT04283656 ↗ Evaluating Drug Interactions Between Doravirine With Estradiol and Spironolactone in Healthy Transgender Women Recruiting Thomas Jefferson University Phase 1 2020-04-01 Transgender women living with Human Immunodeficiency Virus (HIV) may prioritize gender-affirming hormonal therapy over antiretroviral drug therapy. Hormonal therapy typically consists of oral estradiol and spironolactone, which induce drug-metabolizing enzymes after prolonged administration. This study evaluates the bi-directional potential drug interaction between the antiretroviral drug, doravirine, when co-administered with estradiol and spironolactone.
NCT04429152 ↗ ADORE: Efficacy of DORavirine in Adults Living With HIV Experiencing Virological Failure on First-line Efavirenz-based Antiretroviral Therapy With NNRTI Resistance Not yet recruiting Willem Daniel Francois Venter Phase 3 2020-07-01 This is a pilot study investigating the efficacy of Doravirine (DOR) in combination with Lamivudine (3TC) and Tenofovir Disoproxil Fumarate (TDF) administered over 48 weeks in adults living with HIV-1 experiencing virological failure on first-line Efavirenz-based antiretroviral therapy with non-nucleoside reverse transcriptase inhibitor resistance
NCT04433780 ↗ DORA: The Safety of Doravirine-based First-line Antiretroviral Therapy for Women of Reproductive Potential Living With HIV in South Africa Not yet recruiting Willem Daniel Francois Venter Phase 3 2020-07-01 This is a pilot study investigating the safety of Doravirine (DOR) in combination with Lamivudine (3TC) and Tenofovir Disoproxil Fumarate (TDF) administered over 48 weeks in women of reproductive potential living with HIV-1 switched from Efavirenz or Dolutegravir-based antiretroviral therapy on metabolic and neuropsychiatric outcomes.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Delstrigo

Condition Name

Condition Name for Delstrigo
Intervention Trials
Hiv 3
Weight Gain 2
HIV-1-infection 2
Osteoporosis 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Delstrigo
Intervention Trials
Body Weight 2
HIV Infections 2
Acquired Immunodeficiency Syndrome 2
Weight Gain 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Delstrigo

Trials by Country

Trials by Country for Delstrigo
Location Trials
South Africa 2
Denmark 1
Spain 1
Canada 1
France 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Delstrigo
Location Trials
Pennsylvania 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Delstrigo

Clinical Trial Phase

Clinical Trial Phase for Delstrigo
Clinical Trial Phase Trials
Phase 4 3
Phase 3 2
Phase 1 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Delstrigo
Clinical Trial Phase Trials
Not yet recruiting 4
Recruiting 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Delstrigo

Sponsor Name

Sponsor Name for Delstrigo
Sponsor Trials
Willem Daniel Francois Venter 2
Thomas Jefferson University 1
David Garcia Cinca 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Delstrigo
Sponsor Trials
Other 7
Industry 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Boehringer Ingelheim
AstraZeneca
Baxter
McKinsey
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.